本文言語 | English |
---|---|
ページ(範囲) | 3266-3268 |
ページ数 | 3 |
ジャーナル | Leukemia and Lymphoma |
DOI | |
出版ステータス | Published - 2020 |
ASJC Scopus subject areas
- 血液学
- 腫瘍学
- 癌研究
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia and Lymphoma, 2020, p. 3266-3268.
研究成果: Letter › 査読
}
TY - JOUR
T1 - Clinical characteristics and outcomes of duodenal-type follicular lymphoma
AU - Abe, Ryohei
AU - Mori, Takehiko
AU - Tanigawa, Tomohiko
AU - Koda, Yuya
AU - Hosoe, Naoki
AU - Sakurai, Masatoshi
AU - Kikuchi, Taku
AU - Kato, Jun
AU - Shimizu, Takayuki
AU - Ogata, Haruhiko
AU - Kanai, Takanori
AU - Sasaki, Aya
AU - Kameyama, Kaori
AU - Okamoto, Shinichiro
N1 - Funding Information: TM received research funding from MSD, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; TK received personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, Takeda Pharmaceutical, and Bristol-Myers Squibb; JK received personal fees from Astellas Pharma, Otsuka Pharmaceutical, Janssen Pharma, Pfizer, Takeda Pharmaceutical, and JCR Pharmaceuticals; TS received personal fees from Janssen Pharma, Kyowa Kirin, Takeda Pharmaceutical, Celgene, Ono Pharmaceutical, and Eisai; SO received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis Pharma, Bristol-Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi & Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization, and personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, and Takeda Pharmaceutical.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85088458148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088458148&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1795162
DO - 10.1080/10428194.2020.1795162
M3 - Letter
C2 - 32696685
AN - SCOPUS:85088458148
SN - 1042-8194
SP - 3266
EP - 3268
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
ER -